Expects FX to impact growth of Pharma business.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson Reports Earnings: Did it Beat Estimate Forecasts?
- JNJ Gains after Better-than-Expected Q4 Results
- Johnson & Johnson expects some 2022 headwinds to continue in 2023
- Genmab announces 2022 net sales of DARZALEX $7.98B
- Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33